Technology Appraisal Committee Meeting (Committee B)

Minutes: Confirmed

Date and Time: Thursday 1 February 2018, from 10am to 5pm

Venue: Prospero House
241 Borough High Street
London
SE1 1GA

Present:
1. Dr Amanda Adler (Chair) Present for all notes
   Chair for notes 1 to 30
2. Dr Sanjeev Patel (Vice-Chair) Present for all notes
   Chair for notes 31 to 40
3. Mr Diar Fattah Present for all notes
4. Ms Susan Faulds Present for all notes
5. Dr Mark Glover Present for all notes
6. Mr Richard James Hoddes Present for all notes
7. Dr Sanjay Kinra Present for all notes
8. Dr Nicholas Latimer Present for notes 31 to 41
   (Observer for notes 7 to 15 and note 19 to 27)
9. Mr Christopher O'Regan Present for notes 1 to 30
10. Professor Stephen Palmer Present for all notes
11. Dr Danielle Preedy Present for all notes
12. Mrs Pamela Rees Present for all notes
13. Dr Stephen Smith Present for all notes
14. Dr Nicky Welton Present for all notes
15. Mr Nigel Westwood Present for all notes
16. Dr Stuart Williams Present for all notes

In attendance:

Meindert Boysen Programme Director, National Institute for Health and Care Excellence Present for all notes

Dr Elisabeth George Associate Director, National Institute for Health and Care Excellence Present for notes 1 to 18

Jeremy Powell Project Manager, National Institute for Health and Care Excellence Present for all notes

Sandra Aleknavice Administrator, National Institute for Health and Care Excellence Present for all notes
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Notes Present For</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Ekeledo</td>
<td>Project Manager, National Institute for Health and Care Excellence</td>
<td>Present for notes 31 to 41</td>
</tr>
<tr>
<td>Mandy Tonkinson</td>
<td>Administrator, National Institute for Health and Care Excellence</td>
<td>Present for notes 31 to 41</td>
</tr>
<tr>
<td>Dr Mary Hughes</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>Present for notes 1 to 30</td>
</tr>
<tr>
<td>Jasdeep Hayre</td>
<td>Technical Adviser, National Institute for Health and Clinical Excellence</td>
<td>Present for notes 1 to 30</td>
</tr>
<tr>
<td>Thomas Strong</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>Present for notes 1 to 30</td>
</tr>
<tr>
<td>Ahmed Elsada</td>
<td>Technical Adviser, National Institute for Health and Clinical Excellence</td>
<td>Present for notes 1 to 30</td>
</tr>
<tr>
<td>Orsolya Balogh</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>Present for notes 31 to 41</td>
</tr>
<tr>
<td>Ian Wall</td>
<td>Technical Adviser, National Institute for Health and Clinical Excellence</td>
<td>Present for notes 31 to 41</td>
</tr>
<tr>
<td>Professor Peter Clark</td>
<td>Chair of NHS England Chemotherapy Clinical Reference Group and National Clinical Lead for CDF – NHS England expert</td>
<td>Present for notes 1 to 30</td>
</tr>
<tr>
<td>Professor Martin Hoyle</td>
<td>Associate Professor in Health Economics, Peninsula Technology Assessment Group – ERG representative</td>
<td>Present for notes 1 to 15</td>
</tr>
<tr>
<td>Professor Joanne Lord</td>
<td>Director, Southampton Health Technology</td>
<td>Present for notes 19 to 27</td>
</tr>
</tbody>
</table>
Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib.
(partial review of TA171) [ID667], lenalidomide for previously untreated multiple myeloma [ID474] and guselkumab for treating moderate to severe plaque psoriasis [ID1075].

2. The Chair welcomed Dr Nicholas Latimer to his first meeting as a member of the Appraisal Committee.

3. The Chair informed the Committee of the non-public observers at this meeting: Joost de Foolter, Jane Jacobi, Alan Lamb, Edgar Masanga and Kate Weir.

4. Apologies were received from Professor John Cairns and Mr Mark Chapman.

Any other Business

5. The Committee were given an update on the expected timelines for other appraisals.

Notes from the last meeting

6. The minutes of the Committee meetings held on 16 November 2017 and 4 January 2018 were approved.

Appraisal of lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib (partial review of TA171) [ID667]

Part 1 – Open session

7. The Chair welcomed the invited experts: Professor Peter Clark and Professor Martin Hoyle to the meeting and they introduced themselves to the Committee.

8. The Chair welcomed company representatives from Celgene to the meeting.

9. The Chair asked all Committee members to declare any relevant interests

9.1. Dr Amanda Adler, Dr Sanjeev Patel, Mr Diar Fattah, Ms Susan Faulds, Dr Mark Glover, Mr Richard James Hoddes, Dr Sanjay Kinra, Mr Christopher O'Regan, Professor Stephen Palmer, Dr Danielle Preedy, Mrs Pamela Rees, Dr Stephen Smith, Dr Nicky Welton, Mr Nigel Westwood and Dr Stuart Williams all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib (partial review of TA171) [ID667].

9.2. Dr Nicholas Latimer declared a personal specific financial interest before the meeting as he attended an advisory board meeting for Celgene and has also provided a training course for Janssen

9.3.1 It was agreed that this declaration would prevent Dr Latimer from participating in this section of the meeting.

10. The Chair asked all NICE Staff to declare any relevant interests.
10.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib (partial review of TA171) [ID667].

11. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

11.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib (partial review of TA171) [ID667].

12. The Chair introduced the additional information submitted by the company and the Evidence Review Group critique of this information.

13. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

14. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960) and all public attendees left the meeting.

15. The Chair then thanked the Evidence Review Group representative and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

16. Discussion on confidential information continued. This information was supplied by the company.

17. The Committee continued to discuss the clinical and cost effectiveness of lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy with bortezomib (partial review of TA171) [ID667].

17.1. The committee decision was based on consensus.

18. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of lenalidomide for previously untreated multiple myeloma [ID474]

Part 1 – Open session

19. The Chair welcomed the invited experts: Professor Joanne Lord, Neelam Kalita, Dr Jonathan Shepherd, Mr Michael Brown, Mrs Shelagh McKinray, Dr Karthik
Ramasamy and Dr Matthew Streetly to the meeting and they introduced themselves to the Committee.

20. The Chair welcomed company representatives from Celgene to the meeting.

21. The Chair asked all Committee members to declare any relevant interests

21.1. Dr Amanda Adler, Dr Sanjeev Patel, Mr Diar Fattah, Ms Susan Faulds, Dr Mark Glover, Mr Richard James Hoddes, Dr Sanjay Kinra, Mr Christopher O'Regan, Professor Stephen Palmer, Dr Danielle Preedy, Mrs Pamela Rees, Dr Stephen Smith, Dr Nicky Welton, Mr Nigel Westwood and Dr Stuart Williams all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenalidomide for previously untreated multiple myeloma [ID474].

21.2. Dr Nicholas Latimer declared a personal specific financial interest before the meeting as he attended an advisory board meeting for Celgene and has also provided a training course for Janssen

9.3.1 It was agreed that this declaration would prevent Dr Latimer from participating in this section of the meeting.

22. The Chair asked all NICE Staff to declare any relevant interests.

22.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenalidomide for previously untreated multiple myeloma [ID474].

23. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

23.1. Professor Joanne Lord, Neelam Kalita, Dr Jonathan Shepherd and Mr Michael Brown declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of lenalidomide for previously untreated multiple myeloma [ID474].

23.2. Mrs Shelagh McKinray declared a non-personal specific financial interest as Myeloma UK receives grants from a number of pharmaceutical companies, including Celgene. It has also received honoraria for speakers and payments for travel and expenses for educational events.

23.2.1. It was agreed that this declaration would not prevent Mrs McKinray from participating in this section of the meeting.

23.3. Dr Karthik Ramasamy declared a personal specific financial interest as he has received speaker fees from Celgene. In addition, his hospital trust has received research grants from Celgene.
23.3.1. It was agreed that this declaration would not prevent Dr Ramasamy from participating in this section of the meeting

23.4. Dr Matthew Streetly declared a personal specific financial interest as he has received speaker fees from Janssen.
23.4.1. It was agreed that this declaration would not prevent Dr Streetly from participating in this section of the meeting

24. The Chair introduced the lead team, Mrs Susan Faulds, Mr Christopher O'Regan and Mr Nigel Westwood who gave presentations on the clinical effectiveness and cost effectiveness of lenalidomide for previously untreated multiple myeloma [ID474].

25. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

26. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

27. The Chair then thanked the experts, Evidence Review Group representatives and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

28. Discussion on confidential information continued. This information was supplied by the company.

29. The Committee continued to discuss the clinical and cost effectiveness of lenalidomide for previously untreated multiple myeloma [ID474].

29.1. The committee decision was based on consensus.

30. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of guselkumab for treating moderate to severe plaque psoriasis [ID1075]

Part 2 – Closed session

31. The Committee were given a presentation on following the Fast Track Appraisal (FTA) process and were reminded that in the FTA process experts and Evidence Review Group representatives are generally not invited to Committee meetings.

Part 1 – Open session

32. The Chair welcomed company representatives from Janssen to the meeting.

33. The Chair asked all Committee members to declare any relevant interests

33.1. Dr Amanda Adler, Dr Sanjeev Patel, Mr Diar Fattah, Ms Susan Faulds, Dr Mark Glover, Mr Richard James Hoddes, Dr Sanjay Kinra, Dr Nicholas
Latimer, Professor Stephen Palmer, Dr Danielle Preedy, Mrs Pamela Rees, Dr Stephen Smith, Dr Nicky Welton, Mr Nigel Westwood and Dr Stuart Williams all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of guselkumab for treating moderate to severe plaque psoriasis [ID1075].

33.2. Mr Christopher O'Regan declared before the meeting that he has a personal specific financial interest as he is employed by Merck Sharp and Dohme, who manufacture infliximab (one of the comparator drugs).

9.3.1 It was agreed that this declaration would prevent Mr O'Regan from participating in this section of the meeting.

34. The Chair asked all NICE Staff to declare any relevant interests.

34.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of guselkumab for treating moderate to severe plaque psoriasis [ID1075].

35. The Chair introduced technical adviser, Ian Wall who gave a presentation on the clinical effectiveness and cost effectiveness of guselkumab for treating moderate to severe plaque psoriasis [ID1075].

36. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

37. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

38. The Chair then thanked the company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

39. Discussion on confidential information continued. This information was supplied by the company.

40. The Committee continued to discuss the clinical and cost effectiveness of guselkumab for treating moderate to severe plaque psoriasis [ID1075].

40.1. The committee decision was based on consensus.

41. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting
42. Tuesday 6 March 2018 at 10am to 5pm Prospero House, 241 Borough High Street, London SE1 1GA.